🇺🇸 FDA
Pipeline program

IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion.

D419EC00001

Phase 2 small_molecule active

Quick answer

IMFINZI 50 mg/mL concentrate for solution for infusion., IMJUDO 20 mg/ml concentrate for solution for infusion. for Advanced Solid Tumors is a Phase 2 program (small_molecule) at AstraZeneca AB with 1 ClinicalTrials.gov record(s).

Program details

Company
AstraZeneca AB
Indication
Advanced Solid Tumors
Phase
Phase 2
Modality
small_molecule
Status
active

Clinical trials